Absence of cross-reactivity of SR90107A/ORG31540 pentasaccharide with antibodies to heparin-PF4 complexes developed in heparin-induced thrombocytopenia.
New carbohydrate-based anticoagulants devoid of the side effects of unfractionated heparin are currently under development and show a major potential for patients with heparin-induced thrombocytopenia (HIT) who still require efficient antithrombotic therapy. As HIT is usually associated with antibodies to heparin-platelet factor 4 (H-PF4) complexes, cross-reactivity of the heparin pentasaccharide SR90107A/ORG31540 was tested in the presence of PF4 with the plasma from 49 patients with HIT. No cross-reactivity was observed whatever the pentasaccharide concentrations. Although more extensive studies are required for excluding its total absence of immunogenicity and pathogenicity, this pentasaccharide is a candidate for use in emergency situations in patients with HIT.
Amiral
J
J
Serbio Research Laboratory, Gennevilliers, France.
Lormeau
J C
JC
Marfaing-Koka
A
A
Vissac
A M
AM
Wolf
M
M
Boyer-Neumann
C
C
Tardy
B
B
Herbert
J M
JM
Meyer
D
D
D001323:Autoantibodies / Q000276:immunology*; D003429:Cross Reactions; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005343:Fibrinolytic Agents / Q000276:immunology* / Q000627:therapeutic use; D006493:Heparin / Q000009:adverse effects* / Q000276:immunology; D006801:Humans; D046911:Macromolecular Substances; D008297:Male; D009844:Oligosaccharides / Q000276:immunology* / Q000627:therapeutic use; D010978:Platelet Factor 4 / Q000276:immunology*; D011182:Postoperative Care; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000276:immunology*; D013927:Thrombosis / Q000188:drug therapy
D001323:Autoantibodies; D005343:Fibrinolytic Agents; D046911:Macromolecular Substances; D009844:Oligosaccharides; C064764:PENTA; D010978:Platelet Factor 4; D006493:Heparin